Objective: To compare neoadjuvant chemotherapy (nCT) with CAPOX alone versus neoadjuvant chemoradiotherapy (nCRT) with capecitabine in locally advanced rectal cancer (LARC) with uninvolved mesorectal fascia (MRF). Background Data: nCRT is associated with higher surgical complications, worse long-term functional outcomes, and questionable survival benefits. Comparatively, nCT alone seems a promising alternative treatment in lower-risk LARC patients with uninvolved MRF. Methods: Patients between June 2014 and October 2020 with LARC within 12 cm from the anal verge and uninvolved MRF were randomly assigned to nCT group with 4 cycles of CAPOX (Oxaliplatin 130 mg/m2 IV day 1 and Capecitabine 1000 mg/m2 twice daily for 14 d. Repeat every 3 wk) or nCRT group with Capecitabine 825 mg/m² twice daily administered orally and concurrently with radiation therapy (50 Gy/25 fractions) for 5 days per week. The primary end point is local-regional recurrence-free survival. Here we reported the results of secondary end points: histopathologic response, surgical events, and toxicity. Results: Of the 663 initially enrolled patients, 589 received the allocated treatment (nCT, n=300; nCRT, n=289). Pathologic complete response rate was 11.0% (95% CI, 7.8-15.3%) in the nCT arm and 13.8% (95% CI, 10.1-18.5%) in the nCRT arm (P=0.33). The downstaging (ypStage 0 to 1) rate was 40.8% (95% CI, 35.1-46.7%) in the nCT arm and 45.6% (95% CI, 39.7-51.7%) in the nCRT arm (P=0.27). nCT was associated with lower perioperative distant metastases rate (0.7% vs. 3.1%, P=0.03) and preventive ileostomy rate (52.2% vs. 63.6%, P=0.008) compared with nCRT. Four patients in the nCT arm received salvage nCRT because of local disease progression after nCT. Two patients in the nCT arm and 5 in the nCRT arm achieved complete clinical response and were treated with a nonsurgical approach. Similar results were observed in subgroup analysis. Conclusions: nCT achieved similar pCR and downstaging rates with lower incidence of perioperative distant metastasis and preventive ileostomy compared with nCRT. CAPOX could be an effective alternative to neoadjuvant therapy in LARC with uninvolved MRF. Long-term follow-up is needed to confirm these results.

Circulating tumor DNA (ctDNA) enables genomic profiling of colorectal cancer. We investigated therapeutic targets by performing ctDNA panel-captured sequencing of 152 blood samples from advanced stage patients, from which somatic mutations and potentially actionable targets were evaluated. An additional 11 matched tissue samples were retrospectively obtained to verify target validity. The mutation frequencies of 1,127 collective genetic variants identified in our study strongly correlated with those of multiple public databases (Pearson R2 = 0.92, P < 0.0001). The clonal fraction of driver genes was 90.3%, which was significantly higher than that of potential passenger genes (58.12%). Totally, 90 drug-sensitive genes from 56 patients (36.84%) were identified, including recurring targets PIK3CA, FBXW7, EGFR, BRAF, and NRAS. Various resistance mechanisms of anti-EGFR antibodies were revealed via ctDNA profiling, with 29 patients individually exhibiting multiple mechanisms, suggesting considerable resistance heterogeneity in our study population. Of the matched tissue/blood pairs, 88.14% of tissue-derived mutations were detected in ctDNA, and 88.9% of actionable targets were validated. The mutational landscape of ctDNA was highly consistent with tissue databases, and ctDNA profiling showed favorable concordance with tumor tissues in our matched analysis. Thus, comprehensive ctDNA genotyping is a promising noninvasive alternative to biopsy-derived analysis for determining targeted therapy in advanced colorectal cancer.

Anastomotic leakage after colorectal surgery is a major and life-threatening complication that occurs more frequently than expected. Intraoperative judgment in predicting potential leakage has shown extremely low sensitivity and specificity. The lack of a model for predicting anastomotic leakage might explain this insufficient judgment. We aimed to propose a clinical parameters-based model to predict anastomotic leakage after laparoscopic total mesorectal excision (TME).This study was a retrospective analysis of a prospectively designed colorectal cancer dataset. In total, 1968 patients with a laparoscopic TME were enrolled from November 1, 2010, to March 20, 2014. The independent risk factors for anastomotic leakage were identified, from which the parameters-based model for leakage was developed.Anastomotic leakage was noted in 63 patients (3.2%). Male sex, a low level of anastomosis, intraoperative blood loss, diabetes, the duration time of the surgery, and low temperature were significantly associated by the bivariate analysis and the Cochran-Mantel-Haenszel test with an increased risk. From these factors, the logistic regression model identified the following 4 independent predictors: male sex (risk ratio [RR] = 1.85, 95% confidence interval [CI]: 1.13-4.87), diabetes (RR = 2.08, 95% CI: 1.19-5.8), a lower anastomosis level (RR = 3.41, 95% CI: 1.17-6.71), and a high volume of blood loss (RR = 1.03, 95% CI: 1.01-1.05). The locally weighted scatterplot smoothing regression showed an anastomosis within 5 cm from the anus and intraoperative blood loss of >100 mL as the cutoff values for a significantly increased risk of leakage. Based on these independent factors, a parameters-based model was established by the regression coefficients. The high and low-risk groups were classified according to scores of 3-5 and 0-2, with leakage rates of 8.57% and 1.66%, respectively (P < 0.001).This parameters-based model could predict the risk of anastomotic leakage following laparoscopic rectal cancer. After further validation, this model might facilitate the intraoperative recognition of high-risk patients to perform defunctional stomas.

Purpose. The purpose of the current study was to analyze the influence of radiological “disappearing liver metastasis” (DLM) on the efficacy and prognosis of patients with colorectal liver metastases (CRLM) undergoing conversion therapy. Methods. Patients with CRLM by the multidisciplinary team (MDT) of the First Affiliated Hospital of Chongqing Medical University were retrospectively enrolled from January 2014 to January 2021. The relationship between the occurrence and recurrence of DLM and different clinical factors was analyzed. Results. Thirty-five of the 113 patients (31.0%) with initially unresectable CRLM developed DLM, and of the 361 lesions, 177 disappeared (49.0%). Within 6 months, 6-12 months, and 12-24 months groups, the recurrence rate was 3.4%, 16.8%, and 34.8%, but there is no recurrence in after 24 months group. There was a statistical difference between chemotherapy alone and chemotherapy combined with the targeted therapy group on the occurrence of DLM (58.3% vs. 37.1%, ). There were significant differences between 10 mm group on occurrence of DLM（76.7% vs. 30.4%, ) and between 5-10 mm group and >10 mm group also (70.0% vs. 30.4%, ). Through univariate and multivariate analyses, it was concluded that age ( , ) and treatment regimens ( , ) had a significant influence on the progression-free survival (PFS) time of DLM. Conclusion. Younger patients, who use chemotherapy alone to achieve a therapeutic effect, might have better survival benefits when the lesions do not progress within 2 years after the appearance of DLMs.